REDWOOD CITY, Calif., April 14, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced multiple presentations on its hypoxia-activated prodrug, TH-302. The presentations will take place at the 2009 American Association for Cancer Research (AACR) Annual Meeting being held April 18 - 22, 2009, at the Colorado Convention Center in Denver, CO.
